Navigation Links
Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work,Productivity in Patients with Rheumatoid Arthritis

One Groundbreaking Study Showed 11 Percent Fewer RA Patients Reported Job Loss When Treated With HUMIRA Combination Therapy Compared to Methotrexate Alone

BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ -- Rheumatoid arthritis (RA) is one of the most common causes of disability in the Western world. New data released today show that rheumatoid arthritis (RA) patients treated with Abbott's HUMIRA(R) (adalimumab) stayed working longer, had fewer absences and reported greater improvements in work performance.

Results from three studies were presented today at the European League Against Rheumatism (EULAR) annual congress in Barcelona. One groundbreaking study, PRevention Of Work Disability (PROWD), investigated the effect that HUMIRA therapy can have on the length of time RA patients remain at work. This was the first prospective, placebo-controlled, anti-tumor necrosis factor (TNF) study that investigated this effect. PROWD showed that significantly more patients taking methotrexate (MTX) alone reported job loss or imminent job loss after 56 weeks compared with those treated with a combination of HUMIRA and MTX.

A second study of patient-reported measures in paid workers and homemakers with early RA suggested that treatment with HUMIRA and MTX significantly improved their ability to perform their responsibilities at two years. A third study showed that RA patients treated with HUMIRA worked significantly longer compared with patients taking disease-modifying anti-rheumatic drugs (DMARDs).

"The data show that treatment with HUMIRA may allow patients to be more productive both at home and in the workplace," said Paul Emery, M.D., professor of rheumatology, Leeds University, UK.

Five million people worldwide -- mostly between the ages of 25 and 55 -- are currently living with RA, which most often affects the hands, feet and wrists. Typically, joint damage can occur within two years of the onset of the disease. RA can interfere with a person's ability to work due to joint pain, fatigue and joint tenderness and damage. Several studies have shown that patients with RA have limited employment possibilities and reduced productivity at work.

    Study Highlights:

    -- PROWD is a multi-center, randomized, 56-week controlled trial that

       examined the effect of HUMIRA plus MTX versus placebo plus MTX on job

       loss due to all causes and imminent job loss in 148 early RA patients.

       Although the changes in job loss related to all causes -- not specific

       to disability alone -- did not reach significance between weeks 16 and

       56, results showed that significantly more patients on MTX alone

       reported job loss compared to patients taking HUMIRA plus MTX during

       the entire period of 56 weeks (40 percent vs. 19 percent).  The

       investigators concluded that HUMIRA plus MTX reduced RA-related job

       loss and reduced work time lost in patients with early RA more than MTX


    -- DE032 is an economic companion study to PREMIER, a two-year,

       double-blind controlled study that compared the effectiveness of

       HUMIRA, MTX and the combination of the two drugs in treating early RA.

       The DE032 study compared HUMIRA plus MTX (n=219) to MTX alone (n=214)

       on patient-reported measures of work performance in both paid workers

       and homemakers.  Results showed that after two years, paid workers and

       homemakers taking MTX alone missed significantly more workdays than

       patients taking HUMIRA plus MTX (26 vs. 15 and 14 vs. 7, respectively).

       In addition, patients on HUMIRA plus MTX were 21 percent more likely to

       gain or retain employment compared to patients on MTX alone at the end

       of two years.

    -- DE033, an open label DMARD registry controlled study, examined the

       long-term impact on employment tenure and likel
ihood of stopping work

       over 24 months for RA patients on HUMIRA versus those on a DMARD.

       Multivariate regression analyses controlled for the baseline

       characteristic differences between the two populations while comparing

       the outcomes.  Over the two-year period, patients working at the time

       of study enrollment in the HUMIRA group worked more than seven months

       longer and were 36 percent less likely to stop working than the

       patients in the DMARD registry.

"Rheumatoid arthritis can have a profound impact on the lives of patients. Within three years of diagnosis some people who develop the condition have to give up full-time employment," said Rebecca Hoffman, M.D., divisional vice president, Immunology Development, Abbott. "The results of the studies suggest the benefit of HUMIRA combined with MTX extends beyond the clinical scope."

HUMIRA is approved to treat adult patients with moderately to severely active rheumatoid arthritis. More than 190,000 patients worldwide are currently being treated with HUMIRA.

About Rheumatoid Arthritis

Unlike osteoarthritis, the most common form of arthritis, RA is an autoimmune disease where joints are inflamed, which may lead to damage of the joints' interior and the surrounding bone. The joints most commonly affected during the beginning of the disease are the smaller joints of the fingers, feet and wrists. The elbows, knees, ankles and hips can be affected, but less often. Although there is no cure for RA, people continue to seek treatments that not only alleviate the pain and inflammation but also slow disease progression, thereby inhibiting the joint damage that can hinder patients from performing daily activities.

More information on RA and current treatment options can be found at

Important Safety Information About HUMIRA

Globally, prescribing information v aries; refer to the individual country product label for complete information. For U.S. safety information, visit

Serious infections, sepsis, rare cases of tuberculosis (TB), and opportunistic infections, including fatalities, have been reported with the use of TNF antagonists, including HUMIRA. Many of the serious infections have occurred in patients on concomitant immunosuppressive therapy that, in addition to their RA could predispose them to infections. Patients must be monitored closely for infections, including tuberculosis, before, during and after treatment with HUMIRA. Treatment should not be initiated in patients with active infections until infections are controlled. HUMIRA should not be used by patients with active TB or other severe infections such as sepsis and opportunistic infections. Patients who develop new infections while using HUMIRA should be monitored closely. HUMIRA should be discontinued if a patient develops a new serious infection until infections are controlled. Physicians should exercise caution when considering use of HUMIRA in patients with a history of recurring infection or with underlying conditions that may predispose patients to infections.

TNF-blocking agents have been associated with reactivation of hepatitis B (HBV) in patients who are chronic carriers of the virus. Some cases have been fatal. Patients at risk for HBV infection should be evaluated for prior evidence of HBV infection before initiating HUMIRA.

The combination of HUMIRA and anakinra is not recommended.

TNF antagonists, including HUMIRA, have been associated in rare cases with demyelinating disease and serious allergic reactions. Rare reports of pancytopenia including aplastic anemia have been reported with TNF-blocking agents. Adverse events of the haematologic system, including medically significant cytopenia have been infrequently reported with HUMIRA.

More cases of malignancies including lymphoma have been observed among patients receiving a TNF antagonist compared with control patients in clinical trials. The size of the control group and limited duration of the controlled portions of studies precludes the ability to draw firm conclusions. Furthermore, there is an increased background lymphoma risk in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease, which complicates the risk estimation. During the long-term open-label trials with HUMIRA, the overall rate of malignancies was similar to what would be expected for an age, gender and race matched general population. With the current knowledge, a possible risk for the development of lymphomas or other malignancies in patients treated with a TNF antagonist cannot be excluded.

In clinical studies with another TNF antagonist, a higher rate of serious congestive heart failure (CHF) related adverse events including worsening CHF and new onset CHF have been reported. Cases of worsening CHF have also been reported in patients receiving HUMIRA. Physicians should exercise caution when using HUMIRA in patients who have heart failure and monitor them carefully. HUMIRA should not be used in patients with moderate or severe heart failure.

The most frequently reported adverse event (>1/10 patients) at least possibly causally related to HUMIRA is injection site reaction (including pain, swelling, redness or pruritus). Other common adverse events (reported by >1/100 patients) at least possibly causally related to HUMIRA include lower respiratory infections (including pneumonia, bronchitis), viral infections (including influenza, herpes infections), candidiasis, bacterial infection (including urinary tract infections), upper respiratory infection, lymphopenia, dizziness (including vertigo), headache, neurologic sensation disorders (including paraesthesias), infection, irritation or inflammation of the eye, cough, nasopharyngeal pa in, diarrhea, abdominal pain, stomatitis and mouth ulceration, nausea, hepatic enzymes increased, rash, dermatitis and eczema, pruritus, hair loss, musculoskeletal pain, pyrexia, fatigue (including asthenia and malaise).


HUMIRA is the only fully human monoclonal antibody approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS, an arthritis of the spine) and Crohn's disease in the U.S. and Europe. HUMIRA resembles antibodies normally found in the body. It works by blocking tumor necrosis factor alpha (TNF-alpha), a protein that when produced in excess, plays a central role in the inflammatory responses of immune-mediated diseases. To date, HUMIRA has been approved in 67 countries with more than 190,000 people worldwide currently treated with HUMIRA. Clinical trials are currently under way evaluating the potential of HUMIRA in other immune-mediated diseases.

In Europe, HUMIRA, in combination with methotrexate (MTX), is indicated for the treatment of moderate to severe, active RA in adult patients when the response to disease-modifying anti-rheumatic drugs (DMARDs) including MTX has been inadequate, and for the treatment of severe, active and progressive RA in adults not previously treated with MTX. HUMIRA can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate. HUMIRA has been shown to reduce the rate of progression of joint damage as measured byx-ray and to improve physical function, when given in combination with MTX. Additionally, HUMIRA is indicated for the treatment of active and progressive PsA in adults when the response to previous DMARD-therapy has been inadequate and for the treatment of severe, active AS in adults who have had an inadequate response to conventional therapy.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at

CONTACT: International Media, Kellie Harris, +1-847-937-9789, or U.S.Media, Elizabeth Shea, +1-847-935-2211, or Financial, John Thomas,+1-847-938-2655, all of Abbott

Web site:

Ticker Symbol: (NYSE:ABT)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
3. Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment
4. ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO
5. Separate Sets of Research Show Treatment Improved Quality of Life in as Early as Three Weeks; Patient Adherence to Medication is Multifactorial
6. Isotechnika Announces Interim Three Month Data from Phase 2b Kidney Transplant Trial
7. Spectrum Pharmaceuticals Announces Data From Three Oncology Programs Presented at the American Association of Cancer Research Annual Meeting
8. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
Post Your Comments:
(Date:3/27/2017)... 27, 2017 Invivotek, LLC, a Genesis Biotechnology ... vivo pharmacology contract research organization (CRO), announced the ... newly expanded preclinical research facility in Hamilton, ... cleaner, renewable energy source to reduce costs and lessen ... the Genesis Solar Farm follows Invivotek,s recent expansion from ...
(Date:3/24/2017)... and PUNE, India , March 24, 2017 ... "Spine Bone Stimulators Market: Global Opportunity Analysis and Industry Forecast, 2014-2022," the spine ... to reach $724 million by 2022, growing at a CAGR of 3.6% during ... ... Allied Market Research Logo ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Share, Development, Growth and Demand Forecast to 2022" report to their ... The global wound ... to grow at a CAGR of 6.7% during 2016-2022 Among ... held the largest share in the global market in 2015. Among the ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... , ... The iaedp Foundation, the premier provider of educational programs and training ... the full spectrum of disordered eating, announced today that the 2017 Symposium set a ... states and several countries converged on the Green Valley Resort in Las Vegas. ...
(Date:3/24/2017)... Arizona (PRWEB) , ... March 24, 2017 , ... ... Healing Center, Sedona, Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, ... Luis Delgado, June 9--24, 2017. This sacred and spiritual journey during the ...
(Date:3/24/2017)... PA (PRWEB) , ... March 24, 2017 , ... ... Oncology Nursing Society (ONS) wanted to create a communications platform that positions them ... this goal, Elliance and ONS reinvented their online publication as an always-on, always-fresh ...
(Date:3/24/2017)... Oakland, CA (PRWEB) , ... March 24, 2017 ... ... present on two panels at the Advanced ERISA Benefit Claims Litigation seminar in ... and Creating the Administrative Record, The majority of cases litigated under ERISA involve ...
(Date:3/24/2017)... ... ... Viewers who like to educate themselves on current issues and who enjoy gaining ... issues tend to appreciate and love the "Informed" series, hosted by Rob Lowe. ... causes around the world. , Running for charity has become a multi-million ...
Breaking Medicine News(10 mins):